Amarin’s REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events
pharmaceutical investing Positive Phase 1/2 Results of AKCEA-APOCIII-LRx Presented at American College of Cardiology Annual Scientific Session & Expo
Amarin Reports Record Fourth Quarter and Full Year 2017 Financial Results and Provides Update on Operations
University of British Columbia to Perform Clinical Study on the Cardiovascular and Cognitive Health Effects of Lexaria’s TurboCBDTM.
pharmaceutical investing Protext Mobility Discusses Potential for Phytofare to treat Type II Diabetes
New Clinical and Pre-Clinical Data Presented at American College of Cardiology Meeting on the Effect of EPA Therapy in Statin-Treated Patients and on Endothelial Function in Exploratory Studies
Angkor Resources Presents Its Proposed 2027 Work Program For Block Viii To The Cambodian Government At The Joint Review Committee
Blue Jay Gold Announces Materials Purchase Agreement With Ocean Partners for Remediation Material at Steller
SAGA Metals Completes Diamond Drill Program at the Wolverine Rare Earth Project - All 22 Holes Totalling 3,241 Metres Intersect Prospective REE-Bearing Alteration
